Proportion reaching target haemoglobin Median · people with CKD (including HD and PD)
Hypoxia‐inducible factor (HIF) stabilisers probably leads to higher proportion reaching target haemoglobin Median compared with placebo (moderate certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Core symptoms of autism · Children aged 6 to 18 years with ASD
1 finding from 1 review
Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD
Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).
1 finding from 1 review
Language · Children aged 6 to 18 years with ASD
1 finding from 1 review
Memory (specific cognitive function) · Children aged 6 to 18 years with ASD
1 finding from 1 review
Adaptive behaviour · Children aged 6 to 18 years with ASD
1 finding from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
1 finding from 1 review
Irritability · Children aged 6 to 18 years with ASD
1 finding from 1 review
Participants with ≥ 1 vomiting episode · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in vomiting (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in nausea (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of vomiting episodes · adults receiving intravenous opioids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea severity · adults receiving intravenous opioids
1 finding from 1 review